J
James N. Ingle
Researcher at Mayo Clinic
Publications - 403
Citations - 52917
James N. Ingle is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 82, co-authored 387 publications receiving 47883 citations. Previous affiliations of James N. Ingle include McMaster University & University of Rochester.
Papers
More filters
Journal ArticleDOI
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
Kristen S. Purrington,Susan L. Slager,Diana Eccles,Drakoulis Yannoukakos,Peter A. Fasching,Peter A. Fasching,Penelope Miron,Jane Carpenter,Jenny Chang-Claude,Nicholas G. Martin,Grant W. Montgomery,Vessela N. Kristensen,Hoda Anton-Culver,Paul J. Goodfellow,William J. Tapper,Sajjad Rafiq,S Gerty,Lorraine Durcan,Irene Konstantopoulou,Florentia Fostira,Athanassios Vratimos,Paraskevi Apostolou,Irene Konstanta,Vassiliki Kotoula,Sotiris Lakis,Meletios A. Dimopoulos,Dimosthenis Skarlos,Dimitrios Pectasides,George Fountzilas,Matthias W. Beckmann,Alexander Hein,Matthias Ruebner,Arif B. Ekici,Arndt Hartmann,Ruediger Schulz-Wendtland,Stefan P. Renner,Wolfgang Janni,Brigitte Rack,Christoph Scholz,Julia Neugebauer,Ulrich Andergassen,Michael P. Lux,Lothar Haeberle,Christine L. Clarke,Nirmala Pathmanathan,Anja Rudolph,Dieter Flesch-Janys,Stefan Nickels,Janet E. Olson,James N. Ingle,Curtis Olswold,Seth W. Slettedahl,Jeanette E. Eckel-Passow,S. Keith Anderson,Daniel W. Visscher,Victoria Cafourek,Hugues Sicotte,Naresh Prodduturi,Elisabete Weiderpass,Leslie Bernstein,Argyrios Ziogas,Jennifer Ivanovich,Graham G. Giles,Laura Baglietto,Melissa C. Southey,Veli-Matti Kosma,Hans Fischer,MW Reed,Simon S. Cross,Sandra Deming-Halverson,Martha J. Shrubsole,Qiuyin Cai,Xiao-Ou Shu,Mary B. Daly,Jo Ellen Weaver,Eric A. Ross,Jennifer R. Klemp,Priyanka Sharma,Diana Torres,Diana Torres,Thomas Rüdiger,Heidrun Wölfing,Hans Ulrich Ulmer,Asta Försti,Asta Försti,Thaer Khoury,Shicha Kumar,Robert Pilarski,Charles L. Shapiro,Dario Greco,Päivi Heikkilä,Kristiina Aittomäki,Carl Blomqvist,Astrid Irwanto,Jianjun Liu,Vernon S. Pankratz,Xianshu Wang,Gianluca Severi,Arto Mannermaa,Douglas F. Easton,Per Hall,Hiltrud Brauch,Angela Cox,Wei Zheng,Andrew K. Godwin,Ute Hamann,Christine B. Ambrosone,Amanda E. Toland,Heli Nevanlinna,Celine M. Vachon,Fergus J. Couch +110 more
TL;DR: A polygenic risk score (PRS) for TN breast cancer based on known breast cancer risk variants showed a 4-fold difference in risk between the highest and lowest PRS quintiles, suggesting that genetic variation may be used for TN Breast cancer risk prediction.
Journal ArticleDOI
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma†‡
Ravi D. Rao,Shernan G. Holtan,James N. Ingle,Gary A. Croghan,Lisa A. Kottschade,Edward T. Creagan,Judith S. Kaur,Henry C. Pitot,Svetomir N. Markovic +8 more
TL;DR: Patients with metastatic melanoma (MM) have very few therapy options and based on reports of responses to paclitaxel and carboplatin (PC), 31 patients with MM were treated with PC.
Journal ArticleDOI
Increased HER2 with U.S. Food and Drug Administration-approved antibody.
Patrick C. Roche,James N. Ingle +1 more
Journal ArticleDOI
Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer
Mary Jo Fackler,Zoila Areli Lopez Bujanda,Christopher B. Umbricht,Wei Wen Teo,Soonweng Cho,Zhe Zhang,Kala Visvanathan,Stacie Jeter,Pedram Argani,Chenguang Wang,Jaclyn P. Lyman,Marina De Brot,James N. Ingle,Judy C. Boughey,Kandace P. McGuire,Tari A. King,Lisa A. Carey,Leslie Cope,Antonio C. Wolff,Saraswati Sukumar +19 more
TL;DR: The data suggest that the cMethDNA assay can detect advanced breast cancer, and monitor tumor burden and treatment response in women with metastatic breast cancer.
Journal ArticleDOI
Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032
James N. Ingle,Vera J. Suman,Kendrith M. Rowland,Deepu Mirchandani,Albert M. Bernath,John K. Camoriano,Paul A. S. Fishkin,Daniel A. Nikcevich,Edith A. Perez +8 more
TL;DR: Fulvestrant is a well-tolerated treatment and has efficacy against breast cancers that have progressed after therapy with a third-generation AI.